KDM1A and breast carcinoma: Lysine-specific demethylase 1 (LSD1), a histone demethylase involved in epigenetic EMT regulation, the acquisition of cancer stem cell markers (CSCs), and treatment resistance in breast cancer, could be a promising target for overcoming anti-PD-L1 therapy resistance.